Disclosure under Regulation 30 of SEBI Listing Regulations

Pat Growth 25pctRevenue Growth 20pctExceptional ItemResults View source PDF

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-2.5%1-day move

₹17100.00

prior close

₹18305.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-4.3-4.7-4.7-4.3-2.5-3.5-4.7-2.7-2.7-2.5-1.2-0.2+11.0—

Up moveDown movePending

AI summary

Neuland Laboratories reported strong FY2026 results with consolidated revenue from operations growing 37% to Rs. 2,02,298.54 lakhs from Rs. 1,47,683.73 lakhs in FY2025. Profit after tax increased 40% to Rs. 36,399.84 lakhs from Rs. 26,010.81 lakhs. The Board recommended a final dividend of Rs. 34 per share (340% on face value of Rs. 10). Statutory auditors MSKA & Associates LLP issued unmodified opinions on both standalone and consolidated financial results. The company also announced capacity expansion at its Unit 1 in Telangana - adding 120.5KL capacity at an investment of Rs. 143.4 crores over 12-18 months to meet growing customer demand. Additionally, Dr. Mauricio Futran was appointed as Additional Director.

Likely market impact

Strong financial performance with 37% revenue growth and 40% PAT growth signals healthy business momentum. The capacity expansion indicates management confidence in sustained demand. Clean audit opinion removes key risk concerns for investors.